secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ovid Therapeutics Inc. (OVID)
CIK:        0001636651
Form:       8-K
Filed at:   2024-11-12T23:59:59+00:00
Accession:  0001628280-24-046867
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ovid Q3 net loss $14.0M ($0.20/share); cash $62.7M; pauses CCM Phase 2, advances OV329/OV350
--------------------------------------------------------------------------------

- Net loss of $14.0M ($0.20 per share) vs $11.3M in Q3 2023; royalty revenue $173K.
- Cash and marketable securities $62.7M; expected to fund operations into H2 2026.
- Phase 1 MAD study of OV329 progressing; plans to add cohorts for higher dosing; topline data in 2025.
- Regulatory application for Phase 1 trial of OV350 (KCC2 direct activator) expected in Q4 2024; first-in-human Q1 2025.
- Pause of Phase 2 study of OV888/GV101 in CCM to incorporate competitor trial insights; ROCK2 programs continue.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636651/000162828024046867/0001628280-24-046867-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636651/000162828024046867/ovid-20241112.htm
  HTML page:      https://secwatch.observer/filing/0001628280-24-046867

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer